- IGC Pharma (IGC, Financial) has expanded its Board of Advisors with three industry leaders to boost its Alzheimer's drug development.
- The advisory board will enhance strategic guidance for AI-driven early dementia detection programs.
- New members include Frank Zaccanelli, Robert K. Coughlin, and Joseph H. Mangan, bringing expertise in strategic partnerships, regulatory strategy, and clinical engagements.
IGC Pharma, Inc. (IGC) is reinforcing its strategic direction for Alzheimer's treatment and AI-driven dementia detection by appointing three new members to its Board of Advisors. The company, a leader in innovative biotechnology solutions, is focusing its efforts on advancing drug development programs that leverage artificial intelligence for early detection of dementia.
Frank Zaccanelli, former President of the Dallas Mavericks, joins the board to concentrate on building strategic partnerships and enhancing brand ambassador engagement. His extensive experience in business development and global strategy is expected to provide robust support to IGC's outreach and collaboration efforts in the Alzheimer's arena.
Robert K. Coughlin, recipient of the prestigious 2025 Henri A. Termeer Innovative Leadership Award and former CEO of MassBio, will contribute his knowledge to bolster IGC's regulatory strategy and strengthen pharmaceutical relations. Coughlin's experience in biotech innovation and his role as a public servant position him as a key figure in aligning the company's objectives with industry standards and regulatory requirements.
Joseph H. Mangan, a retired brand strategist, will focus on strategizing partnerships with clinical sites, hospitals, and Alzheimer's foundations. His dedication to humanitarian aid and services aligns with IGC's mission to support vulnerable populations, including those affected by Alzheimer's disease.
Ram Mukunda, CEO of IGC Pharma, expressed optimism about the new appointments, noting that the addition of these industry veterans brings diverse expertise that enriches the company's leadership as it aims to scale its operations responsibly and deliver sustained value to patients and shareholders alike.
IGC Pharma continues to lead in the biotechnology sector with promising initiatives such as its cannabinoid-based therapy, IGC-AD1, which is currently undergoing a Phase 2 trial for agitation in Alzheimer's dementia. Additionally, the company's innovative pipeline includes TGR-63, targeting amyloid plaques, alongside AI-driven programs focusing on neurodegeneration and metabolic dysfunctions.
